Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C - PubMed

Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C

X P Pan et al. J Viral Hepat. 2007 Nov.

Abstract

The aims of this study were to investigate the viral differences among lamivudine-resistant hepatitis B virus (HBV) genotypes B and C in vivo. Fifty-three patients carrying lamivudine-resistant HBV were enrolled in this study. HBV genotypes, Levels of alanine aminotransferase (ALT), HBV DNA levels were monitored during therapy. The polymerase and precore/core promoter genes were amplified by polymerase chain reaction and their products were sequenced directly. Among 53 patients resistant HBV genotypes B and C accounted for 41.50% and 58.50%, respectively. The occurrence of reverse transcriptase rt204I mutants was lower in genotype B (36.36%) than that in genotype C (87.10%), whereas rt204V mutants was higher in genotype B (63.64%) than that in genotype C (12.90%). The occurrence of precore mutation (nt1896A) was higher in genotype B (77.27%) than that in genotype C (32.26%). Serum HBV DNA levels after emergence of lamivudine resistance were higher in genotype C (7.71 +/- 0.80 Log copies/mL) compared with genotype B (6.97 +/- 0.77 Log copies/mL). Multivariate analysis identified pretreatment HBV DNA levels, HBeAg status and HBV genotype as independent factors associated with a shorter time to lamivudine resistance(P = 0.035, P = 0.006 and P = 0.001, respectively). Multivariate analysis showed that HBV genotype (P = 0.004) and pretreatment ALT levels (P = 0.01) was independently associated with YMDD mutational patterns. The results showed that the YMDD mutational patterns, precore mutation and serum HBV DNA levels differ between lamivudine-resistant HBV genotypes B and C in vivo. It is valuable for treatment of lamivudine-resistant HBV in clinic.

Similar articles

• Viral features of lamivudine resistant hepatitis B genotypes A and D.

  Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, Schröter M, Laufs R, Feucht HH. Zöllner B, et al. Hepatology. 2004 Jan;39(1):42-50. doi: 10.1002/hep.20016. Hepatology. 2004. PMID: 14752821

• [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].

  Cao XX, Li J, Qiu LM, Luo YW, Chen YH, Ran Y. Cao XX, et al. Zhonghua Gan Zang Bing Za Zhi. 2009 Sep;17(9):641-4. Zhonghua Gan Zang Bing Za Zhi. 2009. PMID: 19785947 Chinese.

• Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.

  Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J. Sun J, et al. J Med Virol. 2005 Mar;75(3):391-8. doi: 10.1002/jmv.20281. J Med Virol. 2005. PMID: 15648063

• Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern.

  Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S, Tillmann HL. Damerow H, et al. J Med Virol. 2010 Nov;82(11):1850-8. doi: 10.1002/jmv.21902. J Med Virol. 2010. PMID: 20872711 Review.

• Lamivudine resistance in hepatitis B: mechanisms and clinical implications.

  Fischer KP, Gutfreund KS, Tyrrell DL. Fischer KP, et al. Drug Resist Updat. 2001 Apr;4(2):118-28. doi: 10.1054/drup.2001.0190. Drug Resist Updat. 2001. PMID: 11512520 Review.

Cited by

• Role of viral factors in the natural course and therapy of chronic hepatitis B.

  Kao JH. Kao JH. Hepatol Int. 2007 Dec;1(4):415-30. doi: 10.1007/s12072-007-9033-2. Epub 2007 Oct 12. Hepatol Int. 2007. PMID: 19669337 Free PMC article.

• Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus.

  Liu H, Wan Z, She L, Zhu Y, Cai Z, Wu B, Zhuang Q, Ke P, Wu X, Li Z, Huang X. Liu H, et al. Front Pharmacol. 2021 Apr 15;12:648170. doi: 10.3389/fphar.2021.648170. eCollection 2021. Front Pharmacol. 2021. PMID: 33935748 Free PMC article.

• Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.

  Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D. Liu Y, et al. J Viral Hepat. 2011 Apr;18(4):e29-39. doi: 10.1111/j.1365-2893.2010.01360.x. Epub 2010 Sep 6. J Viral Hepat. 2011. PMID: 21392168 Free PMC article.

• Compensatory variances of drug-induced hepatitis B virus YMDD mutations.

  Cai Y, Wang N, Wu X, Zheng K, Li Y. Cai Y, et al. Springerplus. 2016 Aug 12;5(1):1340. doi: 10.1186/s40064-016-3003-x. eCollection 2016. Springerplus. 2016. PMID: 27588233 Free PMC article.

• HBV genotype B/C and response to lamivudine therapy: a systematic review.

  Chen XL, Li M, Zhang XL. Chen XL, et al. Biomed Res Int. 2013;2013:672614. doi: 10.1155/2013/672614. Epub 2013 Nov 19. Biomed Res Int. 2013. PMID: 24364035 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database